0000000000280716
AUTHOR
Karl-christian Bergmann
showing 3 related works from this author
Patients with allergic and eosinophilic asthma in the German severe asthma registry
2015
Targeted treatment strategies for asthma require a precise diagnosis of phenotypes. 308 adult patients (age mean±SD: 50.3±13.5yrs) with severe asthma from the German Severe Asthma Registry (www.german-asthma-net.de) were evaluated based on history of allergy symptoms, results of skin prick tests, total/specific IgE, and blood cell differentials. 121 patients (39%) showed typical signs of allergic asthma including allergic symptoms and a positive skin prick test and/or specific IgE with no elevated blood eosinophils (median total IgE: 222 (range 4-4023) IU/ml, eosinophils: 128 (0-295)/µl, FeNO: 23 (7-300) ppb). 53 (43.8%) of these patients were treated with omalizumab. 50 patients (16%) had …
MACC regional multi-model ensemble simulations of birch pollen dispersion in Europe
2015
Abstract. This paper presents the first ensemble modelling experiment in relation to birch pollen in Europe. The seven-model European ensemble of MACC-ENS, tested in trial simulations over the flowering season of 2010, was run through the flowering season of 2013. The simulations have been compared with observations in 11 countries, all members of the European Aeroallergen Network, for both individual models and the ensemble mean and median. It is shown that the models successfully reproduced the timing of the very late season of 2013, generally within a couple of days from the observed start of the season. The end of the season was generally predicted later than observed, by 5 days or more…
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
2021
Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Rese…